Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Inclusion Criteria: * Have newly diagnosed pathologically proven glioblastoma, isocitric dehydrogenase-1/2 wild-type * Tumor with methyl guanine methyl transferase (MGMT) gene promoter unmethylated * Available paraffin embedded tumor tissue for the study * Have completed standard radiotherapy with or without temozolomide * 18 years of age or older * Able to undergo contrast-enhanced MRI * Have an Eastern Cooperative Oncology Group/World Health Organization performance status ≤ 2 * Size and location of the residual tumor and/or resection cavity must allow to be able to be covered by the sonication field * Have not received any prior treatment with immunotherapeutic agents treatments for glioblastoma or other indications * Have the ability to understand and willingness to sign a written informed consent prior to registration on study. * Be willing and able to comply with the protocol. * Have adequate organ and bone marrow function * Agree to use adequate contraception if appropriate Exclusion Criteria: Patients will be ineligible if they have: * Multifocal tumor (unless all localized in a 50-mm diameter area accessible to ultrasound field) or tumor located in the posterior fossa. * Uncontrolled epilepsy. * Received other investigational agents within 2 weeks of registration * Received prior therapy with or have history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study. * Contraindication to checkpoint inhib…